Oxford BioDynamics PLC PDMR Dealing (1593Q)

TIDMOBD

RNS Number : 1593Q

Oxford BioDynamics PLC

17 June 2020

17 June 2020

Oxford BioDynamics Plc

( "OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing

Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Paul Stockdale, Chief Financial Officer, has purchased 5,000 Ordinary Shares of 1 pence each ("shares") at an average price of 64.95p per share.

Following this transaction, Paul Stockdale is interested in 15,000 Ordinary Shares, representing 0.02% of the Company's current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             Paul Stockdale 
     -------------------------------  -------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Director/PDMR 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/            Initial notification 
       Amendment 
     -------------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             Oxford BioDynamics Plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              2138005Y1TK258O5U928 
     -------------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 1 pence each 
       financial instrument,            ISIN: GB00BD5H8572 
       type of instrument 
       Identification code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the transaction        Acquisition of ordinary shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)             Price(s)   Volume(s) 
                                          0.6495     5,000 
                                                    ---------- 
     -------------------------------  -------------------------------------- 
 d)   Aggregated information             Price    Volume 
       - Aggregated volume                0.6495   5,000 
       - Price                                    ------- 
     -------------------------------  -------------------------------------- 
 e)   Dates of the transactions        16 June 2020 
     -------------------------------  -------------------------------------- 
 f)   Place of the transaction         Outside a trading venue 
     -------------------------------  -------------------------------------- 
 

For further details please contact:

 
 Oxford BioDynamics Plc 
  Jon Burrows, CEO 
  Paul Stockdale, CFO                    [phone] 
 Shore Capital 
  Nominated Adviser and Broker 
  Stephane Auton 
  Edward Mansfield 
  John More                             [phone] 
 FTI Consulting 
  Financial Public Relations Adviser 
  Natalie Garland-Collins               [phone] 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHFFMRTMTJBBTM

(END) Dow Jones Newswires

June 17, 2020 02:00 ET (06:00 GMT)